Holen Sie sich die Stockscreener-App
59.22
2.47%
1.43
Handel nachbörslich:
59.22
Schlusskurs vom Vortag:
$57.79
Offen:
$57.75
24-Stunden-Volumen:
3.92M
Relative Volume:
1.11
Marktkapitalisierung:
$26.37B
Einnahmen:
$2.44B
Nettoeinkommen (Verlust:
$1.36B
KGV:
31.02
EPS:
1.9093
Netto-Cashflow:
$574.14M
1W Leistung:
+2.55%
1M Leistung:
+4.94%
6M Leistung:
+32.19%
1J Leistung:
+65.14%
1-Tages-Spanne:
$57.65
$59.33
1-Wochen-Bereich:
$56.53
$59.33
52-Wochen-Spanne:
$34.08
$60.44
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
59.22 | 25.73B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
525.73 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
797.99 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.00 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.05 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares - Stock Titan
RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ - Stock Titan
Zealand gains $100M in funding from Royalty Pharma (RPRX:NASDAQ) - Seeking Alpha
Zealand Pharma sells rusfertide royalty rights for $100 million - Investing.com
Zealand Pharma sells rusfertide royalty rights for $100 million By Investing.com - Investing.com UK
Behavioral Patterns of RPRX and Institutional Flows - Stock Traders Daily
A potential blood-disorder therapy is at the center of a $100M deal - Stock Titan
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - The Manila Times
Zealand Pharma enters into a USD 100 million royalty - GlobeNewswire
Royalty Pharma PLC (NASDAQ:RPRX) Plans Quarterly Dividend of $0.23 - MarketBeat
Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript - AOL.com
Royalty Pharma PLC $RPRX Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Royalty Pharma PLC $RPRX Stake Boosted by Handelsbanken Fonder AB - MarketBeat
Royalty Pharma publishes transcript of Q2 2026 financial results call - Bitget
How Royalty Pharma’s Stronger H1 2026 Earnings and New Academic Focus At Royalty Pharma (RPRX) Has Changed Its Investment Story - simplywall.st
Should Income Investors Look At Royalty Pharma plc (NASDAQ:RPRX) Before Its Ex-Dividend? - simplywall.st
A3LZUK Bond Profile — Key Metrics - TradingView
A3LZUK Bond Coupon Profile — Rate & Payments - TradingView
Royal Bank of Canada Purchases 23,479 Shares of Royalty Pharma PLC $RPRX - MarketBeat
RPHC5824520 Bond Risk Profile - TradingView
Royalty Pharma (NASDAQ:RPRX) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Royalty Pharma (RPRX) CEO gets share award and gifts partnership interests - Stock Titan
Royalty Pharma plc (RPRX) CFO logs equity award and 18,500-share gift - Stock Titan
Royalty Pharma (NASDAQ: RPRX) EVP gets 11,002-share Class A equity award - Stock Titan
Royalty Pharma (RPRX) EVP gets 8,252 shares, gifts LP interests - Stock Titan
Royalty Pharma plc (RPRX) Stock Forecasts - Yahoo! Finance Canada
JPMorgan Chase & Co. Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Royalty Pharma PLC (RPRX) Stock News Today - TradingKey
Bank of America Corp DE Buys 786,921 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Stock Revenue Strength Masks Thin Earnings - Sahm
Royalty Pharma (NASDAQ:RPRX) Announces Earnings Results, Misses Expectations By $1.23 EPS - MarketBeat
Royalty Pharma Q2 2026 slides: guidance raised on strong growth - Investing.com
Royalty Pharma Q2 Earnings Call Highlights - MarketBeat
Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance - Yahoo Finance
BofA raises Royalty Pharma stock price target on strong results By Investing.com - Investing.com South Africa
BofA raises Royalty Pharma stock price target on strong results - Investing.com
Earnings call transcript: Royalty Pharma lifts 2026 outlook in strong Q2 - Investing.com
Royalty Pharma plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:RPRX) 2026-08-05 - Seeking Alpha
Royalty Pharma PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Royalty Pharma (RPRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Royalty Pharma plc 2026: Revenue $674.14M, EPS $0.04— 10-Q Summary - TradingView
Royalty Pharma (Nasdaq: RPRX) lifts H1 2026 cash flow and profit - Stock Titan
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance
Royalty Pharma Q2 Net Income Falls, Revenue Rises - marketscreener.com
Royalty Pharma reports Q2 2026: Portfolio Receipts $773M, Royalty Receipts up 14% - TradingView
Earnings Flash (RPRX) Royalty Pharma plc Reports Q2 Revenue $674.0M - marketscreener.com
Royalty Pharma raises 2026 receipts outlook to $3.4B-$3.5B - Stock Titan
Cooper Investors PTY Ltd. Has $9.21 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Lazard Asset Management LLC Sells 108,947 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma: At The Right P/E, I'm In (But Not Here) (NASDAQ:RPRX) - Seeking Alpha
Royalty Pharma Reports Strong Q2 2026 Earnings with Growth Guidance Increase - Intellectia AI
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.58%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):